Structure of Belzutifan
CAS No.: 1672668-24-4
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Belzutifan is an inhibitor targeting HIF-2α, used in clear cell renal cell carcinoma (ccRCC) and other tumor studies.
Synonyms: PT2977; MK-6482
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma
Wang, Xuechun ; Duong, Loan ; Qin, Yujing ; Parrotta, Rossella ; Purohit, Paresh Kumar ; Fang, Yihao , et al.
Abstract: Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of kidney cancer. Loss of von Hippel–Lindau (VHL) and the consequent activation of hypoxia-inducible factor-α (HIFα, especially HIF2α) plays an essential role in ccRCC initiation and progression. The approved HIF2α inhibitor belzutifan faces the challenge of resistance, presenting an opportunity of co-targeting HIF2α and another vulnerability. This study elucidates the synthetic essentiality of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) in VHL-deficient ccRCC, uncovering a novel reciprocal regulation between HIF2α and TRAIL. TRAIL was identified as a direct transcriptional target of HIF2α and paradoxically found to be crucial for cell proliferation, primarily by activating the p38 MAPK pathway and facilitating G1/S phase transition. Depletion of endogenous TRAIL or inhibition of HIF2α with belzutifan sensitizes ccRCC cells to recombinant TRAIL, presenting a promising avenue for combination therapy to overcome both TRAIL resistance and belzutifan resistance in treating ccRCC.
Show More >
Keywords: TRAIL ; VHL ; HIF2α ; renal cell carcinoma ; belzutifan ; synthetic essentiality
Show More >
CAS No. : | 1672668-24-4 |
Formula : | C17H12F3NO4S |
M.W : | 383.34 |
SMILES Code : | N#CC1=CC(F)=CC(OC2=CC=C(S(=O)(C)=O)C3=C2[C@@H](F)[C@@H](F)[C@H]3O)=C1 |
Synonyms : |
PT2977; MK-6482
|
MDL No. : | MFCD32197212 |
InChI Key : | LOMMPXLFBTZENJ-ZACQAIPSSA-N |
Pubchem ID : | 117947097 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501 |
Description |
Belzutifan (PT2977), an orally bioavailable and selective inhibitor of HIF-2α, has an IC50 value of 9 nM. As a second-generation HIF-2α inhibitor, it offers enhanced potency and an optimized pharmacokinetic profile. Belzutifan holds promise as a treatment option for clear cell renal cell carcinoma (ccRCC)[1].
|
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT04924075 | Pheochromocytoma/Paraganglioma... More >>|Pancreatic Neuroendocrine Tumor|Von Hippel-Lindau Disease|Advanced Gastrointestinal Stromal Tumor|HIF-2α Mutated Cancers Less << | PHASE2 | RECRUITING | 2029-06-04 | Cedars-Sinai Medical Center ( ... More >>Site 0110), Los Angeles, California, 90048, United States|University of Iowa ( Site 0104), Iowa City, Iowa, 52242, United States|Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site, Baltimore, Maryland, 21287, United States|National Institutes of Health ( Site 0125), Bethesda, Maryland, 20892, United States|Massachusetts General Hospital ( Site 0111), Boston, Massachusetts, 02114, United States|University of Michigan ( Site 0126), Ann Arbor, Michigan, 48109, United States|Washington University-Internal Medicine/Oncology ( Site 0124), Saint Louis, Missouri, 63110, United States|Icahn School of Medicine at Mount Sinai ( Site 0123), New York, New York, 10029, United States|Penn Medicine: University of Pennsylvania Health System-Heme/Onc ( Site 0127), Philadelphia, Pennsylvania, 19104, United States|Vanderbilt University Medical Center ( Site 0107), Nashville, Tennessee, 37232, United States|University of Texas MD Anderson Cancer Center ( Site 0112), Houston, Texas, 77030, United States|Prince of Wales Hospital-Medical Oncology ( Site 1601), Randwick, New South Wales, 2031, Australia|The Royal Melbourne Hospital ( Site 1602), Parkville, Victoria, 3050, Australia|Arthur J.E. Child Comprehensive Cancer Centre ( Site 0203), Calgary, Alberta, T2N 5G2, Canada|Princess Margaret Cancer Centre ( Site 0202), Toronto, Ontario, M5G 2M9, Canada|FALP ( Site 2200), Santiago, Region M. De Santiago, 7500921, Chile|Peking University First Hospital-Urology ( Site 1900), Beijing, Beijing, 100034, China|Sun Yat-sen University Cancer Center ( Site 1905), Guangzhou, Guangdong, 510700, China|Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 1904), Shanghai, Shanghai, 200001, China|West China Hospital of Sichuan University ( Site 1906), Cheng Du, Sichuan, 610041, China|Rigshospitalet ( Site 0304), Copenhagen, Hovedstaden, 2100, Denmark|Rigshospitalet-Department of Endocrinology ( Site 0303), Copenhagen, Hovedstaden, 2100, Denmark|Odense Universitetshospital ( Site 0302), Odense C, Syddanmark, 5000, Denmark|CHU Strasbourg-Hautepierre-Medecine Interne, Endocrinologie et Nutrition ( Site 0402), Strasbourg, Alsace, 67098, France|Institut Paoli-Calmettes-Oncology ( Site 0406), Marseille, Bouches-du-Rhone, 13009, France|Gustave Roussy ( Site 0403), Villejuif, Ile-de-France, 94805, France|H?pitaux Universitaires Paris Sud - H?pital Bicêtre ( Site 0407), Le Kremlin-Bicêtre, Paris, 94270, France|H?pital Edouard Herriot-oncologie ( Site 0405), Lyon, Rhone-Alpes, 69003, France|Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0404), Paris, 75014, France|Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Department of Internal Medicine IV, Division (, München, Bayern, 80336, Germany|Comprehensive Cancer Center Mainfranken-Div. of Endocrinology and Diabetes ( Site 0500), Würzburg, Bayern, 97080, Germany|Universitaetsklinikum Freiburg ( Site 0504), Freiburg, Brandenburg, 79106, Germany|Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 0505), Düsseldorf, Nordrhein-Westfalen, 40225, Germany|Charité Universitaetsmedizin Berlin - Campus Mitte-Department of Endocrinology and Metabolism ( Site, Berlin, 10117, Germany|Semmelweis University-Belgyógyászati és Onkológiai Klinika Hematológia Osztály ( Site 0600), Budapest, 1083, Hungary|Sheba Medical Center-Institute of Endocrinology, Diabetes and Metabolism ( Site 1400), Ramat Gan, 5262100, Israel|Sourasky Medical Center ( Site 1401), Tel Aviv, 6423906, Israel|University of Naples Federico II-Dipartimento di Medicina Clinica e Chirurgia ( Site 0704), Naples, Campania, 80100, Italy|IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 0708), Bologna, 40138, Italy|Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 0701), Brescia, 25123, Italy|Ospedale San Raffaele-Oncologia Medica ( Site 0705), Milano, 20132, Italy|Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Medica Gastrointestinale e Tumori Neuroe, Milano, 20141, Italy|Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma ( Site 0703), Verona, 37134, Italy|Hokkaido University Hospital ( Site 1800), Sapporo, Hokkaido, 060-8648, Japan|Yokohama City University Hospital-Department of Urology ( Site 1804), Yokohama, Kanagawa, 236-0004, Japan|Kochi Medical School Hospital ( Site 1807), Nankoku, Kochi, 783-8505, Japan|National Cancer Center Hospital ( Site 1802), Chuo-ku, Tokyo, 104-0045, Japan|Kyoto University Hospital ( Site 1806), Kyoto, Japan|Tokyo Women's Medical University Adachi Medical Center ( Site 1803), Tokyo, 123-8558, Japan|Universitair Medisch Centrum Utrecht ( Site 1530), Utrecht, 3584 CX, Netherlands|Oslo Universitetssykehus Radiumhospitalet ( Site 2400), Oslo, 0424, Norway|GBUZ Republican Clinical Oncological Dispensary ( Site 0804), Ufa, Baskortostan, Respublika, 450054, Russian Federation|Saint Petersburg State University-Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (, Saint Petersburg, Leningradskaya Oblast, 190020, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 0803), Saint Petersburg, Leningradskaya Oblast, 198255, Russian Federation|Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology MHRF ( Site 0801), Moscow, Moskva, 115522, Russian Federation|Endocrinology Research Center of Rosmedtechnologies-Surgery ( Site 0809), Moscow, Moskva, 117036, Russian Federation|National Cancer Centre Singapore ( Site 1700), Singapore, Central Singapore, 168583, Singapore|Hospital Universitario Central de Asturias-Medical Oncology ( Site 1101), Oviedo, Asturias, 33011, Spain|MD Anderson Cancer Center-Oncology ( Site 1102), Madrid, Madrid, Comunidad De, 28033, Spain|Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1103), Madrid, Madrid, Comunidad De, 28041, Spain|Hospital Universitari Vall d'Hebron ( Site 1100), Barcelona, 08035, Spain|Skanes University Hospital Lund ( Site 1200), Lund, Skane Lan, 221 85, Sweden|Karolinska Universitetssjukhuset Solna ( Site 1202), Stockholm, Stockholms Lan, 171 76, Sweden|Akademiska sjukhuset-Blod- och tum?rsjukdomar ( Site 1201), Uppsala, Uppsala Lan, 751 85, Sweden|Sahlgrenska Universitetssjukhuset-Department of Oncology CTU Clinical Trial Unit ( Site 1204), Gothenburg, Vastra Gotalands Lan, 413 45, Sweden|Ege University Medicine of Faculty ( Site 0900), Bornova, Izmir, 35100, Turkey|Hacettepe Universitesi-oncology hospital ( Site 0901), Ankara, 06230, Turkey|Ankara Bilkent ?ehir Hastanesi. ( Site 0904), Ankara, 06800, Turkey|Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 0902), Istanbul, 34668, Turkey|Addenbrooke's Hospital ( Site 1309), Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom|Royal Free Hospital ( Site 1302), London, England, NW3 2QG, United Kingdom|The Beatson West of Scotland Cancer Centre ( Site 1308), Glasgow, Glasgow City, G12 0YN, United Kingdom|Hammersmith Hospital-Medical Oncology ( Site 1304), London, London, City Of, W12 OHS, United Kingdom Less << |
NCT02974738 | Advanced Solid Tumors|Solid Tu... More >>mor|Solid Carcinoma|Solid Tumor, Adult|ccRCC|RCC, Clear Cell Adenocarcinoma|RCC|Kidney Cancer|Clear Cell Renal Cell Carcinoma|Renal Cell Carcinoma, Metastatic|Renal Cell Carcinoma Recurrent|Renal Cell Carcinoma, Clear Cell Adenocarcinoma|Glioblastoma|Glioblastoma, Adult|GBM|Glioblastoma Multiforme Less << | PHASE1 | ACTIVE_NOT_RECRUITING | 2025-04-14 | - |
NCT03445169 | Healthy | PHASE1 | COMPLETED | 2018-05-26 | Spaulding Clinical, West Bend,... More >> Wisconsin, 53095, United States Less << |
NCT04489771 | Carcinoma, Renal Cell | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-10-04 | Georgetown University Medical ... More >>Center ( Site 0002), Washington, District of Columbia, 20007, United States|Univ of Miami- Sylvester Comprehensive Cancer Center ( Site 0023), Miami, Florida, 33136, United States|Norton Cancer Institute - St. Matthews ( Site 0025), Louisville, Kentucky, 40207, United States|Weinberg Cancer Institute at Franklin Square ( Site 0007), Baltimore, Maryland, 21237, United States|Cancer Partners of Nebraska ( Site 0003), Lincoln, Nebraska, 68510, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0012), Omaha, Nebraska, 68130, United States|New York Oncology Hematology P.C ( Site 0028), Albany, New York, 12206, United States|Roswell Park Cancer Institute ( Site 0038), Buffalo, New York, 14263, United States|Fox Chase Cancer Center ( Site 0026), Philadelphia, Pennsylvania, 19111, United States|Sanford Cancer Center Oncology Clinic ( Site 0031), Sioux Falls, South Dakota, 57104, United States|UT West Cancer Center ( Site 0032), Germantown, Tennessee, 38138, United States|Urology Associates ( Site 0015), Nashville, Tennessee, 37209, United States|University of Texas Southwestern Medical Center at Dallas ( Site 0004), Dallas, Texas, 75390, United States|Baylor Scott & White Medical Center - Temple ( Site 0013), Temple, Texas, 76508, United States|Huntsman Cancer Institute ( Site 0037), Salt Lake City, Utah, 84112, United States|Inova Schar Cancer Institute ( Site 0001), Fairfax, Virginia, 22031, United States|Blue Ridge Cancer Care - Roanoke ( Site 0017), Roanoke, Virginia, 24014, United States|Kadlec Clinic Hematology and Oncology ( Site 0008), Kennewick, Washington, 99336, United States|Macquarie University ( Site 1007), Macquarie University, New South Wales, 2109, Australia|Eastern Health - Box Hill Hospital ( Site 1003), Box Hill, Victoria, 3128, Australia|Peninsula Health Frankston Hospital ( Site 1001), Frankston, Victoria, 3199, Australia|GZA Sint Augustinus ( Site 2003), Wilrijk, Antwerpen, 2610, Belgium|Grand Hopital de Charleroi ( Site 2005), Charleroi, Hainaut, 6000, Belgium|CHU de Liege ( Site 2002), Liège, Liege, 4000, Belgium|UZ Gent ( Site 2004), Gent, Oost-Vlaanderen, 9000, Belgium|UZ Leuven ( Site 2001), Leuven, Vlaams-Brabant, 3000, Belgium|General Hospital of Athens "Alexandra" ( Site 1102), Athens, Attiki, 115 28, Greece|Athens University Hospital ATTIKON ( Site 1100), Chaidari, Attiki, 12 462, Greece|University General Hospital of Larissa ( Site 1101), Larissa, Thessalia, 411 10, Greece|Cork University Hospital ( Site 9053), Cork, T12 DC4A, Ireland|Tallaght University Hospital ( Site 9051), Dublin, D24 NR0A, Ireland|Soroka Medical Center ( Site 4004), Beer Sheva, 8410101, Israel|Rambam Medical Center ( Site 4001), Haifa, 3109601, Israel|Rabin Medical Center ( Site 4002), Petach Tikva, 4941492, Israel|Sourasky Medical Center ( Site 4003), Tel Aviv, 6423906, Israel|Maastricht Universitair Medisch Centrum - MUMC ( Site 5001), Maastricht, Limburg, 6202AZ, Netherlands|Antoni van Leeuwenhoek Ziekenhuis ( Site 5003), Amsterdam, Noord-Holland, 1066 CX, Netherlands|Isala klinieken ( Site 5002), Zwolle, Overijssel, 8025 AB, Netherlands|Erasmus MC ( Site 5000), Rotterdam, Zuid-Holland, 3015 GD, Netherlands|Universitair Medisch Centrum Utrecht ( Site 5004), Utrecht, 3584 CX, Netherlands|Federal state budgetary institution Russian Research Centre of radiology and nuclear medicine ( Site, Moscow, Moskva, 117997, Russian Federation|City Clinical Oncology Hospital No. 1 ( Site 6004), Moscow, Moskva, 129090, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies ( Site 6001), Saint Petersburg, Sankt-Peterburg, 197758, Russian Federation|Clinical Research Center of specialized types medical care-Oncology ( Site 6002), Saint-Petersburg, Sankt-Peterburg, 197758, Russian Federation|Royal Free London NHS Foundation Trust ( Site 9003), London, England, NW3 2QG, United Kingdom|Imperial College Healthcare NHS Trust ( Site 9004), London, London, City Of, W6 8RF, United Kingdom|Churchill Hospital ( Site 9000), Oxford, Oxfordshire, OX3 7LE, United Kingdom|Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 9001), Nottingham, NG5 1PB, United Kingdom Less << |
NCT03401788 | VHL - Von Hippel-Lindau Syndro... More >>me|VHL Gene Mutation|VHL Syndrome|VHL Gene Inactivation|VHL-Associated Renal Cell Carcinoma|VHL-Associated Clear Cell Renal Cell Carcinoma Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2026-03-29 | National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States|Vanderbilt Medical Center, Nashville, Tennessee, 37232, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Aarhus University Hospital, Aarhus, Denmark|Hospital Georges Pompidou, Paris, France|Cambridge University Hospital, Cambridge, United Kingdom Less << |
NCT04995484 | Moderate Hepatic Impairment | PHASE1 | COMPLETED | 2024-01-03 | Orlando Clinical Research Cent... More >>er ( Site 0001), Orlando, Florida, 32809, United States|The Texas Liver Institute ( Site 0002), San Antonio, Texas, 78215, United States Less << |
NCT06677190 | Ovarian Cancer|Ovarian Carcino... More >>ma Less << | PHASE2 | RECRUITING | 2029-06-30 | Brigham and Women's Hospital, ... More >>Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less << |
NCT04994522 | End Stage Renal Disease|Renal ... More >>Impairment Less << | PHASE1 | COMPLETED | 2024-04-11 | Orlando Clinical Research Cent... More >>er ( Site 0001), Orlando, Florida, 32809, United States Less << |
NCT04846920 | Carcinoma, Renal Cell | PHASE1 | ACTIVE_NOT_RECRUITING | 2026-07-21 | Beth Israel Deaconess Medical ... More >>Center ( Site 1002), Boston, Massachusetts, 02215, United States|University of Michigan ( Site 1006), Ann Arbor, Michigan, 48109, United States|Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 1005), Nashville, Tennessee, 37232, United States|University of Texas MD Anderson Cancer Center-Genitourinary Medical Oncology ( Site 1007), Houston, Texas, 77030, United States Less << |
Tags: Belzutifan | PT2977 | Fluorinated Building Blocks | HIF | Organic Building Blocks | Epigenetics | Angiogenesis | Tumor Epigenetics and Gene Regulation | 1672668-24-4
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL